Josh John Carlson

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics
    Josh J Carlson
    Department of Pharmacy, University of Washington, Seattle, Washington JJC, RT, Jr, JG, DLV
    Med Decis Making 33:463-71. 2013
  2. doi Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Clin Ther 35:414-24. 2013
  3. doi The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
  4. doi Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis
    Josh John Carlson
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Cancer Res Clin Oncol 135:1483-93. 2009
  5. doi Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Expert Rev Pharmacoecon Outcomes Res 9:409-16. 2009
  6. doi Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
  7. doi Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer
    Josh J Carlson
    University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
    J Med Econ 14:159-66. 2011

Detail Information

Publications7

  1. doi Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics
    Josh J Carlson
    Department of Pharmacy, University of Washington, Seattle, Washington JJC, RT, Jr, JG, DLV
    Med Decis Making 33:463-71. 2013
    ..The objective of this study was to evaluate the feasibility and outcomes of incorporating value-of-information (VOI) analysis into a stakeholder-driven research prioritization process in a US-based setting...
  2. doi Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Clin Ther 35:414-24. 2013
    ..However, the economic impact of onabotulinumtoxinA treatment for UI due to NDO in the United States remains unknown...
  3. doi The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
    ..The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC)...
  4. doi Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis
    Josh John Carlson
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Cancer Res Clin Oncol 135:1483-93. 2009
    ....
  5. doi Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Expert Rev Pharmacoecon Outcomes Res 9:409-16. 2009
    ..This article reviews the clinical and economic evidence on the use of erlotinib in advanced non-small-cell lung cancer...
  6. doi Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
    ..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
  7. doi Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer
    Josh J Carlson
    University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
    J Med Econ 14:159-66. 2011
    ..Assess the budgetary impact of adding erlotinib for maintenance therapy (MTx) in advanced non-small cell lung cancer (NSCLC) from a US health plan perspective...